Cover Image

Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut–Brain Interaction of Lower Gastrointestinal Tract

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Michael Camilleri, Alexander C. Ford
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Review Article: Drug Approval for Gastroparesis—Suggestions for Improving the Process for Positive Results
by: Michael Camilleri, et al.
Published: (2026)

Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice
by: Sydney Pomenti, et al.
Published: (2025)

Review: Human Intestinal Barrier—Optimal Measurement and Effects of Diet in the Absence of Overt Inflammation or Ulceration
by: Michael Camilleri
Published: (2025)

Prevalence and Burden of Fatigue Across Disorders of Gut–Brain Interaction: Results From the Rome Foundation Global Epidemiology Study
by: Fleur Veldman, et al.
Published: (2026)

Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
by: Camille Lupianez‐Merly, et al.
Published: (2024)

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
by: Christy Riggott, et al.
Published: (2024)

Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea
by: Saam Dilmaghani, et al.
Published: (2025)

Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance and Expansion
by: Cathy Lu, et al.
Published: (2025)

Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort
by: Christy Riggott, et al.
Published: (2025)

Editorial for ‘Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance, and Expansion’
by: Cameron Kendall, et al.
Published: (2025)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
by: Jörn M. Schattenberg, et al.
Published: (2026)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
by: Giovanni Cammarota, et al.
Published: (2024)

Review Article: Individualised Management of Reflux‐Like Symptoms—Strategies Beyond Acid Suppression
by: Peter J. Kahrilas, et al.
Published: (2025)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
by: Manjeet Kumar Goyal, et al.
Published: (2026)

Review article: Seeing Is Believing–The Eosinophilic Oesophagitis Endoscopic Reference Score Can Serve as a Valuable Clinical Trial Endpoint in Eosinophilic Oesophagitis
by: Ikuo Hirano, et al.
Published: (2025)

Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation
by: Erin R. Bonner, et al.
Published: (2025)

Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies
by: Mengmeng Lin, et al.
Published: (2025)

Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection—Questions Focused on Clinical Practice
by: Javier P. Gisbert, et al.
Published: (2026)

Editorial: Gastrointestinal symptoms—A world of differences
by: Kevin W. Olden
Published: (2024)

Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding
by: Darrick K. Li, et al.
Published: (2026)

Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care
by: Vivek C. Goodoory, et al.
Published: (2024)

Research Communication: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
by: Lauren Holtslander, et al.
Published: (2025)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply
by: Anthony O'Connor, et al.
Published: (2024)

Letter: Rifaximin Versus Low FODMAP Diet in IBS : What the Primary Endpoint Does Not Tell Us
by: Luisa Bertin, et al.
Published: (2026)

Stability of Classification Systems for Irritable Bowel Syndrome
by: Mais Khasawneh, et al.
Published: (2025)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
by: Hassan Javed, et al.
Published: (2025)

Women's Health Disorders in a Coeliac Disease Population After Diagnosis—A Nationwide Cohort Analysis
by: Rama Nanah, et al.
Published: (2025)

Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis
by: Alfredo J. Lucendo, et al.
Published: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
by: Nobuharu Tamaki, et al.
Published: (2025)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
by: Maryam Zafer, et al.
Published: (2025)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
by: Jiaqi Shen, et al.
Published: (2026)

Letter: Interpreting Apparent P‐ CAB Superiority for Antithrombotic‐Associated Upper Gastrointestinal Bleeding
by: Xiaoqing Yang, et al.
Published: (2026)

Letter: Assessing the Durability of Treatment Effects: Long‐Term Outcomes of ESWL and ERCP for Pancreatic Duct Stones in Chronic Pancreatitis
by: Wei‐Zhen Tang, et al.
Published: (2024)

Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom
by: Mohsin F. Butt, et al.
Published: (2025)

Editorial: MetALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan?
by: Hannes Hagström, et al.
Published: (2025)

Letter (brief communication): A pilot study of hemp hull bio gut fibre (BGF) to reduce intestinal permeability in IBS‐BAD
by: Camille Lupianez‐Merly, et al.
Published: (2024)

Alterations in Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension: Implications for Disease Progression
by: Qun Zhang, et al.
Published: (2025)

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
by: Benjamin Douglas Liu, et al.
Published: (2025)

Editorial: M et ALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan? Authors' Reply
by: Nobuharu Tamaki, et al.
Published: (2025)

Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow‐Up Study
by: Christy Riggott, et al.
Published: (2025)